Related Experiment Videos
Clinical treatment of dyslipidemia: practice patterns and missed opportunities
1Division of Cardiology, University of North Carolina Cardiovascular Center, University of North Carolina at Chapel Hill, 27599-7075, USA.
Insights
Most patients with coronary artery disease and postsurgical cardiac conditions with dyslipidemia are undertreated for serum lipids, particularly high-density lipoprotein cholesterol (HDL-C). Improved compliance with lipid-modifying therapy can be achieved through nurse case management and prompt treatment initiation.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Dyslipidemia is prevalent in coronary artery disease and postsurgical cardiac patients.
- Current monitoring and treatment of serum lipids, especially high-density lipoprotein cholesterol (HDL-C), are inadequate in these patient groups.
- Adherence to National Cholesterol Education Program (NCEP) target levels is frequently not achieved.
Purpose of the Study:
- To assess the current management of dyslipidemia in patients with coronary artery disease and postsurgical cardiac conditions.
- To identify common lipid-altering therapies prescribed and their appropriateness.
- To explore factors influencing compliance with lipid-modification therapy.
Main Methods:
- Review of patient data for dyslipidemia monitoring and treatment adherence.
- Analysis of prescribed lipid-altering medications, including statins, fibrates, niacin, and resins.
- Evaluation of patient compliance with prescribed therapies.
Main Results:
- Most dyslipidemic patients with coronary artery disease and postsurgical cardiac conditions are not adequately monitored for serum lipids, including HDL-C.
- Lipid-altering therapy is often not prescribed or not managed to NCEP target levels.
- Statins are most common, followed by fibrates and niacin; resins are least common, and drug choices are not always optimal.
- Patient compliance with lipid-modification therapy is generally poor.
Conclusions:
- Significant gaps exist in the monitoring and treatment of dyslipidemia in high-risk cardiac patients.
- Suboptimal drug selection and poor patient compliance hinder effective lipid management.
- Nurse case-management programs, consistent healthcare professional contact, and early post-intervention therapy initiation are crucial for improving compliance and patient outcomes.
Abstract:
Studies have found that most dyslipidemic coronary artery disease and postsurgical cardiac patients are not monitored for serum lipids, especially high-density lipoprotein cholesterol (HDL-C). These patients are not prescribed lipid-altering therapy and are not treated to National Cholesterol Education Program (NCEP) target levels. When prescribed, the most commonly administered drugs are statins, followed by fibrates and niacin. Resins are the least commonly prescribed treatment for dyslipidemia. Unfortunately, drugs chosen are often not the best for each patient. To compound matters, compliance with lipid-modification therapy is poor. Nurse case-management programs, supportive regular contact with healthcare professionals, and immediate postinterventional initiation of therapy significantly improves compliance.